Bitcoin price slips as Strategy stock rises on MSCI index reprieve

Bitcoin price slips as Strategy stock rises on MSCI index reprieve

NEW YORK, Jan 7, 2026, 13:44 (EST) — Regular session

  • Strategy shares outperformed after MSCI paused a plan that could have knocked crypto-treasury firms out of indexes
  • Bitcoin eased and U.S.-listed crypto-linked stocks were mixed in regular trading
  • Traders are watching ETF flows and Friday’s U.S. payrolls report

Strategy shares rose on Wednesday after MSCI backed away from a plan that could have pushed the bitcoin-heavy company out of major benchmarks, even as bitcoin slipped. Bitcoin was down about 0.7% at $91,253 and Strategy was up about 2% in afternoon trade; Coinbase fell about 2.5%.

MSCI said on Tuesday it would keep the current treatment of “digital asset treasury companies” — firms it defines as having crypto holdings worth at least 50% of total assets — and open a broader consultation on how non-operating companies should be handled. Strategy called the decision “a strong outcome for neutral indexing and economic reality” in a post on X after the update. 1

For the stocks, the stakes are mechanical: staying in widely used MSCI indexes can matter for passive funds that track them. DATCOs became popular last year as companies piled into bitcoin and ether, offering a proxy for direct exposure. “It removes a material near-term technical risk,” Owen Lau, an analyst at Clear Street, said, while flagging that the longer-term eligibility debate is still open. 2

Morgan Stanley Investment Management said it filed initial registration statements with the SEC for a Morgan Stanley Bitcoin Trust and a Morgan Stanley Solana Trust, both structured as passive exchange-traded products designed to track the token prices. The proposed listings would add to a crowded U.S. menu of crypto-linked products aimed at investors who want exposure through brokerage accounts. 3

Flows have been a headwind. U.S. spot bitcoin ETFs — exchange-traded funds that hold bitcoin directly — saw $697.2 million of net inflows on Monday but flipped to $243.2 million of net outflows on Tuesday, Farside Investors data showed; Fidelity’s FBTC led redemptions while BlackRock’s IBIT still took in $228.7 million. 4

Bitcoin’s pullback left crypto-linked shares uneven. The iShares Bitcoin Trust ETF fell about 1.5% on the day, while miners Marathon Digital and Riot Platforms traded in opposite directions.

Macro data gave traders another reason to keep positions light. U.S. job openings fell more than expected in November and hiring eased, a JOLTS report showed, while economists polled by Reuters expect Friday’s payrolls report to show only a modest rise in December jobs. 5

The setup can still turn quickly. Bitcoin hovering near the $90,000 level keeps downside risk in play for the higher-beta “treasury” stocks, and MSCI’s broader review could yet revive the exclusion question later this year.

Next up: the U.S. employment report is due at 8:30 a.m. ET on Friday, followed by December consumer prices on Jan. 13. The Federal Reserve’s next policy decision comes Jan. 28 after a two-day meeting. 6

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
Silver price stock SLV slides as spot silver drops; U.S. payrolls report looms
Previous Story

Silver price stock SLV slides as spot silver drops; U.S. payrolls report looms

XRP price today: WisdomTree drops XRP ETF plan as token slides, payrolls in focus
Next Story

XRP price today: WisdomTree drops XRP ETF plan as token slides, payrolls in focus

Go toTop